Related Experiment Video
Updated: Sep 25, 2025
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Partial Response to Small Molecule Inhibition in a Case of Anaplastic Large Cell Lymphoma
Sarah Young1, Amirah Kuzu2, Mike Magill2
1Oncology, Orlando Regional Medical Center, Orlando, USA.
Abstract:
In the era of personalized medicine, small-molecule inhibitors have become key to targeting many malignancies. Multiple hematologic malignancies are driven by small-molecule pathways that are seemingly ripe for such targeting. In this case report, we present a patient who was treated with a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor for what was originally diagnosed as a histiocytic sarcoma. Re-biopsy ultimately revealed an anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL), but his disease initially showed a remarkable response to MEK inhibition. This case illustrates both the importance of obtaining high-quality biopsy specimens for diagnostic and molecular analysis as well as the need for further research into the molecular drivers of T-cell lymphomas that may be amenable to targeted therapies.
Insights
A patient with anaplastic large cell lymphoma (ALCL) initially responded to a MEK inhibitor, despite a misdiagnosis. This highlights the need for accurate molecular profiling in T-cell lymphomas for targeted therapy development.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Personalized medicine utilizes small-molecule inhibitors for targeted cancer therapy.
- Hematologic malignancies often involve small-molecule pathways suitable for targeted inhibition.
- Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors represent a class of targeted agents.
Observation:
- A patient initially diagnosed with histiocytic sarcoma received MEK inhibitor treatment.
- Re-biopsy confirmed the diagnosis as anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL).
- The patient's disease demonstrated an initial significant response to MEK inhibition.
Findings:
- The case highlights a potential, albeit temporary, therapeutic window for MEK inhibitors in ALK-negative ALCL.
- Accurate histopathological and molecular diagnosis is crucial for effective treatment selection.
- Unexpected responses can occur, suggesting complex underlying molecular drivers.
Implications:
- Emphasizes the critical role of high-quality biopsy specimens for precise diagnosis and molecular analysis.
- Underscores the necessity for further research into the molecular underpinnings of T-cell lymphomas.
- Suggests exploring novel targeted therapies for hematologic malignancies based on molecular profiling.
